PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF)

PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF)

This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Peter J. BUONTEMPO, Ronald G. JUBIN, Abraham ABUCHOWSKI, Friedericke KAZO
Format: Patent
Sprache:eng ; spa
Schlagworte:
BEER
BIOCHEMISTRY
CHEMISTRY
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
SPIRITS
VINEGAR
WINE
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The inventive compositions have unexpected therapeutic efficacy, while avoiding or substantially reducing the likelihood of adverse side effects. Esta invención se refiere a conjugados novedosos de PEGx-GCSF, en el cual x es la cantidad de PEG por GCSF y varía de 4 a 8. La invención también se refiere a poblaciones de PEG[x]-GCSF de conjugados de PEGx-GCSF individuales, en las cuales [x] es la cantidad promedio de PEG por GCSF de la población y es de 4 o mayor. Las composiciones de la invención tienen eficacia terapéutica inesperada, al tiempo que evitan o reducen sustancialmente la probabilidad de efectos secundarios adversos.